1. Three people have died from meningococcal disease this year in NSW, two were aged 15-25 years 2. Recent fatal cases had rapid onset with fever, nausea, and vomiting predominating 3. Early identification and rapid treatment can save lives 4. Cases this year are due to serogroup B 5. MenACWY vaccine and MenB vaccine is recommended to anyone who wants to protect against disease.
Meningococcal disease cases are above average for the time of year. All cases in 2022 (29) have been due to serogroup B, three cases have died. A recent cluster of 4 cases, including two deaths, have been in the Illawarra Shoalhaven area. Children 0-4 years and people aged 15-25 years are at highest risk of IMD.
Invasive Meningococcal Disease
IMD is caused by several serogroups of Neisseria meningitidis. Serogroups B, C, W and Y have caused the majority of IMD in Australia. Recent cases have predominately been caused by serogroup B.
IMD is a rare but serious disease. Historically up to 10% of cases have been fatal even with appropriate antibiotic treatment. Survivors are often left with long-term sequelae.
Symptoms of invasive Meningococcal Disease
Early meningococcal disease symptoms can be non-specific and mimic other common illnesses like respiratory or gastro viruses. Onset is often sudden, and illness progresses rapidly.
As soon as a clinician suspects meningitis clinically administer an immediate dose of ceftriaxone or benzylpenicillin and urgently transfer to an ED if not already there. Please refer to Guidelines
Symptoms may include sudden onset of fever, severe headache, neck stiffness, unexplained joint, limb or abdominal pain, a non-blanching rash of red-purple spots or bruises, photophobia, nausea, and vomiting. Symptoms in young children include irritability, difficulty waking, high-pitched crying, and refusal to eat.
The ‘meningococcal rash’ does not always appear, and often occurs late in the illness.
Patients should always be advised to urgently re-attend if symptoms rapidly progress or worsen.
Any person who wants to protect themselves against invasive meningococcal disease can receive MenACWY and MenB vaccines from as early as 6 weeks of age.
The National Immunisation Program (NIP) includes meningococcal vaccination for certain groups and meningococcal vaccines are also available via private prescription. GPs and now pharmacists are now also able to administer meningococcal vaccines for people aged 5 years and over. As vaccine schedules and serogroups covered have changed over time, history of vaccination should not exclude a diagnosis of IMD.
Groups eligible for free vaccine
Meningococcal ACWY vaccine A
All children at 12 months of age Children aged 15-19 years*
Meningococcal B vaccine
Aboriginal children < 2 years of age
People with certain medical conditions that cause increased risk of infection^
*via the school vaccination program, their GP, or registered pharmacist immunisers ^including asplenia, hyposplenia, complement deficiency and those receiving eculizumab treatment
Public Health Response and further information:
Outbreaks of IMD can occur and it is important to urgently notify your Public Health Unit on 1300 066 055 of any suspected case to facilitate management of close contacts and prevent further cases.
Maroubra Medicare Urgent Care Clinic (UCC) is now open The Maroubra Medicare Urgent Care Clinic (UCC) is now open, seven days a week, from 8.00am to 8.00pm. It was officially launched by member for Kingsford Smith, the hon Matt Thistlethwaite MP (pictured at the launch with CESPHN CEO Nathalie Hansen…
Media Release: Central and Eastern Sydney PHN releases Healthy Ageing Strategy to empower older people In response to the increasing longevity and rapid growth of the older population the Central and Eastern Sydney Primary Health Network (CESPHN) is proud to release its new Healthy Ageing Strategy 2023-2028. This comprehensive strategy…
Immunisation Weekly Update: Are your vaccines ready for summer? In the summer season, storms are more likely to occur, which can lead to power outages. Refer to the Cold Chain Toolkit to ensure all vaccination storage requirements are in place should an outage occur. Disposal of Zostavax® Zostavax® vaccine will…
Immunisation Weekly Update: COVID-19 XBB.1.5 vaccine onboarding The Australian Government has accepted the latest advice from ATAGI on the use of the new COVID-19 XBB 1.5 vaccine as part of the National COVID-19 Vaccine Program. All sites currently participating in the COVID-19 Vaccination Program will be onboarded for the three…
Immunisation Weekly Update: Increase in COVID-19 infection cases ATAGI notes a recent increase in COVID-19 cases since November 2023 across Australia and encourages all eligible people who have not yet had their recommended 2023 COVID-19 vaccine dose/s to receive them as soon as possible. A first 2023 dose is recommended…
Immunisation Weekly Update: Vaccination coverage in RACF Australian Immunisation Register (AIR) data suggests that only 36% of people aged 70+ living in the central and eastern Sydney PHN region are immunised against Pneumococcal diseases. Immunisation providers are reminded to check AIR immunisation history statements of patients going into Residential Aged…
Immunisation Weekly Update: Introduction of Shingrix® to the NIP From 1 November 2023, the shingles vaccine Shingrix® will replace Zostavax® on the National Immunisation Program (NIP) schedule for the prevention of shingles and post-herpetic neuralgia. It will be available for eligible people most at risk of complications from shingles. A…
NSW urged to prepare for heat wave Severe heatwave conditions are forecast in NSW in the coming days. Please read the NSW Health media release about taking steps to prevent heat-related illness. For further information about staying safe in a heatwave, visit Beat the heat and stay well during hot…